U.S. Markets open in 3 hrs 3 mins

Shareholder Alert: Robbins Arroyo LLP Announces MacroGenics, Inc. (MGNX) Sued for Misleading Shareholders

SAN DIEGO & ROCKVILLE, Md.--(BUSINESS WIRE)--

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of MacroGenics, Inc. (MGNX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 6, 2019 and June 3, 2019. MacroGenics is a biopharmaceutical company that discovers and develops antibody-based therapeutics for cancer treatment. One of its products includes margetuximab, which is being tested for use in patients with HER2-positive metastatic breast cancer.

If you suffered a loss as a result of MacroGenics' misconduct, click here.

MacroGenics, Inc. (MGNX) Accused of Misleading Shareholders

According to the complaint, in February 2019, MacroGenics announced positive results for its pivotal Phase III SOPHIA study of Margetuximab, stating that the trial met its primary endpoint of prolongation of progression-free survival (PFS) in "patients treated with the combination of margetuximab plus chemotherapy compared to trastuzamb. Following the announcement of these results, MacroGenics' share prices skyrocketed. Then, on May 13, 2019, the American Society of Clinical Oncologists ("ASCO") posted the study's abstract, disclosing that the October 2018 PFS analysis of the SOPHIA trial resulted in only 0.9 month improvements in PFS. However, MacroGenics continued to tout the results of its SOPHIA study, and on May 15, 2019, issued another press release stating it met "the first sequential primary endpoint of PFS in head-to-head with current standard of care" and that the "median overall survival (OS) at the time was prolonged by 1.7 months." Then, on June 4, 2019, MacroGenics revealed during the ASCO meeting that its latest PFS and OS results had actually been conducted in October 2018, and the OS interim analysis showed no statistical difference between the drug treatments. On this news, the price of MacroGenics common stock fell over 23% over the next three trading days, to close at $14.51, and has yet to recover.

MacroGenics, Inc. (MGNX) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsarroyo.com
Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190923005807/en/